Although the European Medicines Agency (EMA) recently approved a recombinant FVIIa (rFVIIa) for the treatment of acute bleeding in postpartum hemorrhage (PPH), its use is associated with risks of ...
Results that may be inaccessible to you are currently showing.
Hide inaccessible results
Feedback